Comparison · NCT00268996-sae
Darapladib 160 mg EC Tablet vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Darapladib 160 mg EC Tablet vs Placebo: serious adverse events. Trial comparisons, record NCT00268996-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00268996-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.267 | 0.207 | 0.338 | wilson | |
| Risk in group 2 | 0.298 | 0.231 | 0.375 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0306 | -0.129 | 0.067 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.897 | 0.634 | 1.27 | log | |
| Odds ratio, group 1 over group 2 | 0.86 | 0.529 | 1.4 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Darapladib 160 mg EC Tablet than on Placebo | 32.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Darapladib 160 mg EC Tablet | Eligible participants received darapladib 160 mg EC tablet once daily for 52 weeks. Participants were instructed to administer one tablet (swallowed intact and not chewed) in the morning each day with food. | 46 | 172 | EG001 |
| Group 2 | Placebo | Eligible participants received the matching placebo for 52 weeks. Participants were instructed to administer one tablet (swallowed intact and not chewed) in the morning each day with food. | 45 | 151 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse events (AEs) were recorded from the time a participant consents to participate until completion of follow-up period (10 to 21 days after discontinuation of treatment). On-treatment (up to 52 weeks) serious-AE (SAE) and non-SAE are reported.
Source ClinicalTrials.gov
Trial
- Title
- Integrated Biomarker And Imaging Study - 2
- NCT number
- NCT00268996
- Phases
- PHASE2
- Conditions
- Atherosclerosis
- Interventions
- SB-480848, SB-480848 matching placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-02-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00268996?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00268996-sae